Paris, France, February 14, 2008 - GenOdyssee S.A., a biotechnology company dedicated to the discovery and development of improved ‘next generation’ blockbuster protein therapeutic products, announced that it has received notice of allowance from the United States Patent and Trademark Office (USPTO) of its Patent Application N° 10/691,653 covering its lead anti-HCV IFN-alpha product GEA007.1 for application in the treatment of hepatitis C. GEA007.1 is a naturally occurring mutant of human IFN alpha 17. In preclinical studies, GEA007.1 demonstrated improved intrinsic antigenotype 1 antiviral properties without increased toxicity at therapeutic doses used in HCV treatments, as compared to standard of care IFN-alpha 2 drugs... [PDF] GenOdyssee's Press Release -
Monday, April 14, 2008
GenOdyssee : Notice of Allowance from U.S. Patent Office for Improved Interferon-Alpha Aimed at Hepatitis C
Paris, France, February 14, 2008 - GenOdyssee S.A., a biotechnology company dedicated to the discovery and development of improved ‘next generation’ blockbuster protein therapeutic products, announced that it has received notice of allowance from the United States Patent and Trademark Office (USPTO) of its Patent Application N° 10/691,653 covering its lead anti-HCV IFN-alpha product GEA007.1 for application in the treatment of hepatitis C. GEA007.1 is a naturally occurring mutant of human IFN alpha 17. In preclinical studies, GEA007.1 demonstrated improved intrinsic antigenotype 1 antiviral properties without increased toxicity at therapeutic doses used in HCV treatments, as compared to standard of care IFN-alpha 2 drugs... [PDF] GenOdyssee's Press Release -
